Bli medlem
Bli medlem

Du är här

2017-02-07

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons on 3 February 2017

Bagsværd, Denmark, 7 February 2017
- This document discloses the data of the transaction(s) made in Novo Nordisk
shares by the company's board members, executives and their associated
persons in accordance with Article 19 of Regulation No. 596/2014 on market
abuse.

The company's board members, executives and their associated persons have
given Novo Nordisk power of attorney on their behalf to publish trading in
Novo Nordisk shares by the company's board members, executives and their
associated persons.

Definitions and background information:

Publication

Publication shall take place no later than three working days after the
trading by board members, executives or their associated persons. Publication
is only required when the total amount of transactions of a specific board
member/executive and his/her associated persons in any one calendar year has
reached 20,000 EUR.
Who are board members, executives and associated persons?

Board members and executives are members of the Board of Directors and
Executive Management, respectively, of Novo Nordisk A/S. Associated persons
are defined as the following persons associated to a board member/executive:
1) spouse or cohabitant, 2) children under the age of 18 years, 3) Other
relatives defined as brothers, sisters, parents, grandparents, children,
grandchildren, cousins etc. who have shared the same household with a board
member or executive for a period of at least one year on the date of the
given transaction and 4) any legal persons, trust, or partnership, the
managerial responsibilities of which are discharged by a board
member/executive or by a person referred to in items 1)-3) above, which is
directly or indirectly controlled by such a person, which is set up for the
benefit of such a person, or the economic interests of which are
substantially equivalent to those of such a person.

What is trading/transaction?
Trading is any kind of transaction, including shares and share related
securities purchased or otherwise acquired, sold or otherwise disposed,
gifts, mortgages, heritage and grants, allotments and exercise of options.

What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq Copenhagen and ADRs
listed on New York Stock Exchange, except for ADRs held in 401(k) retirement
plan by US-based employees. The ID code is the code (ISIN DK0060534915) of
the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York
Stock Exchange.

What is date and place of transaction?

Date of transaction is the actual transaction date. The place of transaction
is the actual place of transaction, i.e. Nasdaq Copenhagen or New York Stock
Exchange.

What is the volume and price of transaction and aggregated information?

The volume of transaction is the number of shares (of DKK 0.20 nominal value)
or other financial instruments traded. In case of a single transaction the
price is the price of that single transaction. In case of multiple
transactions, when the transactions relates to the same financial instrument,
are of the same nature, are executed on the same day and are executed on the
same place, the volume must be aggregated. The price of the aggregated
transactions is the weighted average price.

The exchange rate of the Danish Central Bank (Nationalbanken) on the date of
transaction is used for calculating the transaction value in DKK in case of
ADRs listed on New York Stock Exchange.

Further information

-----------------------------------------------------------------
| Media: |
| Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com |
| Ken Inchausti (US) +1 609 514 8316 kiau@novonordisk.com |
| |
| Investors: |
| Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com |
| Melanie Raouzeos +45 3075 3479 mrz@novonordisk.com |
| Hanna Ögren +45 3079 8519 haoe@novonordisk.com |
| Anders Mikkelsen +45 3079 4461 armk@novonordisk.com |
| Kasper Veje (US) +1 609 235 8567 kpvj@novonordisk.com |
-----------------------------------------------------------------

Company announcement No 9 / 2017

Company announcement No 9 / 2017
http://hugin.info/2013/R/2076567/780945.pdf

---------------------------------------
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.